Business Context and Reporting Period
This Form 8-K filing by Cerecor Inc. (not Avalo Therapeutics, Inc.) is dated April 10, 2019, with the report date of April 12, 2019. The filing addresses significant corporate governance changes, including the appointment of a new Executive Chairman and the resignation of the Chief Executive Officer, as well as resulting non-compliance with Nasdaq listing rules regarding independent directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and corporate governance.
- Executive Compensation (Simon Pedder): Base salary of $350,000 per year; $50,000 signing bonus; target annual discretionary cash bonus of 60% of base salary.
- Equity Grants: 250,000 restricted stock units (50,000 immediately vested); 300,000 stock options (time-based vesting); 300,000 performance-based stock options (vesting tied to stock price milestones of $8.00, $10.50, and $13.00).
Material Changes Versus Prior Period
The filing details the following material changes effective April 15, 2019:
- Leadership Transition: Peter Greenleaf resigned as Chief Executive Officer (CEO) but remains on the Board. Simon Pedder was appointed Executive Chairman of the Board.
- Principal Executive Officer: Joseph Miller, the Chief Financial Officer, will serve as the "principal executive officer" for SEC filing purposes.
- Committee Composition: Dr. Pedder stepped off the Audit Committee and Nominating and Corporate Governance Committee due to his new employee status, leaving the Audit Committee with only two independent directors.
Guidance, Outlook, Risks, and Contingencies
Nasdaq Compliance Risks: The Company is currently non-compliant with Nasdaq Listing Rule 5605(c)(2)(A) because the Audit Committee must comprise three independent directors, but currently has only two. Additionally, the Company is non-compliant with the majority independent board requirement.
Cure Periods and Plans:
- Audit Committee: The Company has a cure period expiring at the next annual stockholders' meeting or October 8, 2019, whichever is earlier, to regain compliance.
- Majority Independent Board: The Company has 45 calendar days to submit a plan to regain compliance, with a potential 180-day extension to evidence compliance if the plan is accepted.
Management Commentary: The Board intends to conduct a director search process to fill the vacancy and expects to be compliant with Nasdaq rules by the end of the cure periods. The CEO's resignation was not related to any disagreement with the Company.
Important Facts for Investor Verification
- Verify the timeline for the Board's director search to ensure compliance with Nasdaq's independent director requirements before the October 8, 2019 deadline.
- Confirm the status of the amendment to the 2016 Equity Incentive Plan, as a portion of Dr. Pedder's equity grants requires stockholder approval.
- Monitor the transition of duties from the former CEO to the new Executive Chairman and the interim Principal Executive Officer.
- Review the specific vesting conditions for the performance-based stock options tied to share price milestones ($8.00, $10.50, $13.00).